

7. Literaturverzeichnis

1. COLLINS, F. S., GREEN, E. D., GUTTMACHER, A. E. & GUYER, M. S. (2003) A vision for the future of genomics research, *Nature*, 422, 835-47.
2. WATSON, J. D. & CRICK, F. H. (1953) Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid, *Nature*, 171, 737-8.
3. RAZIN, A. & RIGGS, A. D. (1980) DNA methylation and gene function, *Science*, 210, 604-10.
4. KIM, G. D., NI, J., KELESOGLU, N., ROBERTS, R. J. & PRADHAN, S. (2002) Co-operation and communication between the human maintenance and de novo DNA (cytosine-5) methyltransferases, *Embo J*, 21, 4183-95.
5. RHEE, I., BACHMAN, K. E., PARK, B. H. et al. (2002) DNMT1 and DNMT3b cooperate to silence genes in human cancer cells, *Nature*, 416, 552-6.
6. ROBERT, M. F., MORIN, S., BEAULIEU, N. et al. (2003) DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells, *Nat Genet*, 33, 61-5.
7. OKANO, M., BELL, D. W., HABER, D. A. & LI, E. (1999) DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development, *Cell*, 99, 247-57.
8. RAMSAHOYE, B. H., BINISZKIEWICZ, D., LYKO, F. et al. (2000) Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a, *Proc Natl Acad Sci U S A*, 97, 5237-42.
9. SVED, J. & BIRD, A. (1990) The expected equilibrium of the CpG dinucleotide in vertebrate genomes under a mutation model, *Proc Natl Acad Sci U S A*, 87, 4692-6.
10. CHAN, M. F., VAN AMERONGEN, R., NIJJAR, T. et al. (2001) Reduced rates of gene loss, gene silencing, and gene mutation in Dnmt1-deficient embryonic stem cells, *Mol Cell Biol*, 21, 7587-600.
11. CLARK, S. J. & MELKI, J. (2002) DNA methylation and gene silencing in cancer: which is the guilty party?, *Oncogene*, 21, 5380-7.
12. GARDINER-GARDEN, M. & FROMMER, M. (1987) CpG islands in vertebrate genomes, *J Mol Biol*, 196, 261-82.
13. TAKAI, D. & JONES, P. A. (2002) Comprehensive analysis of CpG islands in human chromosomes 21 and 22, *Proc Natl Acad Sci U S A*, 99, 3740-5.

14. BRANDEIS, M., FRANK, D., KESHET, I. et al. (1994) Sp1 elements protect a CpG island from de novo methylation, *Nature*, 371, 435-8.
15. ISSA, J. P., OTTAVIANO, Y. L., CELANO, P. et al. (1994) Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon, *Nat Genet*, 7, 536-40.
16. AHUJA, N., LI, Q., MOHAN, A. L., BAYLIN, S. B. & ISSA, J. P. (1998) Aging and DNA methylation in colorectal mucosa and cancer, *Cancer Res*, 58, 5489-94.
17. HOAL-VAN HELDEN, E. G. & VAN HELDEN, P. D. (1989) Age-related methylation changes in DNA may reflect the proliferative potential of organs, *Mutat Res*, 219, 263-6.
18. TONIOLO, D., MARTINI, G., MIGEON, B. R. & DONO, R. (1988) Expression of the G6PD locus on the human X chromosome is associated with demethylation of three CpG islands within 100 kb of DNA, *Embo J*, 7, 401-6.
19. HOLLIDAY, R., HO, T. & PAULIN, R. (1996) Epigenetic mechanism of Gene Regulation. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 47-61.
20. BOYES, J. & BIRD, A. (1992) Repression of genes by DNA methylation depends on CpG density and promoter strength: evidence for involvement of a methyl-CpG binding protein, *Embo J*, 11, 327-33.
21. HSIEH, C. L. (1994) Dependence of transcriptional repression on CpG methylation density, *Mol Cell Biol*, 14, 5487-94.
22. CHEN, C., YANG, M. C. & YANG, T. P. (2001) Evidence that silencing of the HPRT promoter by DNA methylation is mediated by critical CpG sites, *J Biol Chem*, 276, 320-8.
23. BELL, A. C. & FELSENFELD, G. (2000) Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene, *Nature*, 405, 482-5.
24. HENDRICH, B. & BIRD, A. (1998) Identification and characterization of a family of mammalian methyl-CpG binding proteins, *Mol Cell Biol*, 18, 6538-47.
25. NAN, X., NG, H. H., JOHNSON, C. A. et al. (1998) Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex, *Nature*, 393, 386-9.
26. JONES, P. L., VEENSTRA, G. J., WADE, P. A. et al. (1998) Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription, *Nat Genet*, 19, 187-91.

27. BIRD, A. P. (1995) Gene number, noise reduction and biological complexity, *Trends Genet*, 11, 94-100.
28. FUTSCHER, B. W., OSHIRO, M. M., WOZNIAK, R. J. et al. (2002) Role for DNA methylation in the control of cell type specific maspin expression, *Nat Genet*, 31, 175-9.
29. WALSH, C. P., CHAILLET, J. R. & BESTOR, T. H. (1998) Transcription of IAP endogenous retroviruses is constrained by cytosine methylation, *Nat Genet*, 20, 116-7.
30. YODER, J. A., WALSH, C. P. & BESTOR, T. H. (1997) Cytosine methylation and the ecology of intragenomic parasites, *Trends Genet*, 13, 335-40.
31. LI, E. (2002) Chromatin modification and epigenetic reprogramming in mammalian development, *Nat Rev Genet*, 3, 662-73.
32. LI, E., BEARD, C. & JAENISCH, R. (1993) Role for DNA methylation in genomic imprinting, *Nature*, 366, 362-5.
33. BEARD, C., LI, E. & JAENISCH, R. (1995) Loss of methylation activates Xist in somatic but not in embryonic cells, *Genes Dev*, 9, 2325-34.
34. PANNING, B. & JAENISCH, R. (1996) DNA hypomethylation can activate Xist expression and silence X-linked genes, *Genes Dev*, 10, 1991-2002.
35. JONES, P. A. & BAYLIN, S. B. (2002) The fundamental role of epigenetic events in cancer, *Nat Rev Genet*, 3, 415-28.
36. FEINBERG, A. P. (2001) Methylation meets genomics, *Nat Genet*, 27, 9-10.
37. COSTELLO, J. F., FRUHWALD, M. C., SMIRAGLIA, D. J. et al. (2000) Aberrant CpG island methylation has non-random and tumour-type-specific patterns, *Nat Genet*, 24, 132-8.
38. GREGER, V., PASSARGE, E., HOPPING, W., MESSMER, E. & HORSTHEMKE, B. (1989) Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma, *Hum Genet*, 83, 155-8.
39. EHRLICH, M., GAMA-SOSA, M. A., HUANG, L. H. et al. (1982) Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells, *Nucleic Acids Res*, 10, 2709-21.
40. MURATA, J., TADA, M., IGGO, R. D. et al. (1997) Nitric oxide as a carcinogen: analysis by yeast functional assay of inactivating p53 mutations induced by nitric oxide, *Mutat Res*, 379, 211-8.

41. HATADA, I., HAYASHIZAKI, Y., HIROTSUNE, S., KOMATSUBARA, H. & MUKAI, T. (1991) A genomic scanning method for higher organisms using restriction sites as landmarks, *Proc Natl Acad Sci U S A*, 88, 9523-7.
42. LISITSYN, N. & WIGLER, M. (1993) Cloning the differences between two complex genomes, *Science*, 259, 946-51.
43. FROMMER, M., MCDONALD, L. E., MILLAR, D. S. et al. (1992) A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands, *Proc Natl Acad Sci U S A*, 89, 1827-31.
44. HAYATSU, H., WATAYA, Y., KAI, K. & IIDA, S. (1970) Reaction of sodium bisulfite with uracil, cytosine, and their derivatives, *Biochemistry*, 9, 2858-65.
45. HERMAN, J. G., GRAFF, J. R., MYOHANEN, S., NELKIN, B. D. & BAYLIN, S. B. (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands, *Proc Natl Acad Sci U S A*, 93, 9821-6.
46. EGGER, G., LIANG, G., APARICIO, A. & JONES, P. A. (2004) Epigenetics in human disease and prospects for epigenetic therapy, *Nature*, 429, 457-63.
47. JONES, P. A. & TAYLOR, S. M. (1980) Cellular differentiation, cytidine analogs and DNA methylation, *Cell*, 20, 85-93.
48. ISSA, J. P., GARCIA-MANERO, G., GILES, F. J. et al. (2004) Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies, *Blood*, 103, 1635-40.
49. BANELLI, B., GELVI, I., DI VINCI, A. et al. (2005) Distinct CpG methylation profiles characterize different clinical groups of neuroblastic tumors, *Oncogene*, 24, 5619-28.
50. MALINEN, T., PALOTIE, A., PAKKALA, S. et al. (1991) Acceleration of chronic myeloid leukemia correlates with calcitonin gene hypermethylation, *Blood*, 77, 2435-40.
51. HUSON, S. M. (1994) Neurofibromatosis 1: a clinical and genetic overview. In: Huson S. M., Hughes R. A. C. (eds.) *The neurofibromatoses*. Chapman and Hall Medical, London, pp 160-203.
52. HUSON, S. M., HARPER, P. S. & COMPSTON, D. A. (1988) Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales, *Brain*, 111 (Pt 6), 1355-81.
53. KORF, B. R., HUSON, S. M., & VISKOCHIL (1997) Report of the working group on neurofibroma. The National Neurofibromatosis Foundation, New York. pp.4-27.

54. WEISS, S. W. & GOLDBLUM, J. R. (2001) Benign tumors of peripheral nerves. In: WEISS, S. W. & GOLDBLUM (eds.) *Soft Tissue Tumors*, 4th ed. St. Louis: Mosby, pp.1111-207.
55. DUCATMAN, B. S., SCHEITHAUER, B. W., PIEPGRAS, D. G., REIMAN, H. M. & ILSTRUP, D. M. (1986) Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases, *Cancer*, 57, 2006-21.
56. EVANS, D. G., BASER, M. E., MCGAUGHRAN, J. et al. (2002) Malignant peripheral nerve sheath tumours in neurofibromatosis 1, *J Med Genet*, 39, 311-4.
57. FERNER, R. E., LUCAS, J. D., O'DOHERTY, M. J. et al. (2000) Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1, *J Neurol Neurosurg Psychiatry*, 68, 353-7.
58. ZOLLER, M., REMBECK, B., AKESSON, H. O. & ANGERVALL, L. (1995) Life expectancy, mortality and prognostic factors in neurofibromatosis type 1. A twelve-year follow-up of an epidemiological study in Goteborg, Sweden, *Acta Derm Venereol*, 75, 136-40.
59. SORENSEN, S. A., MULVIHILL, J. J. & NIELSEN, A. (1986) Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms, *N Engl J Med*, 314, 1010-5.
60. SHANNON, K. M., O'CONNELL, P., MARTIN, G. A. et al. (1994) Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders, *N Engl J Med*, 330, 597-601.
61. STUMPF, D. A., ALKSNE, J. F., ANNEGERS, J. F. et al. (1988) Neurofibromatosis conference statement. *Arch Neurol*, 45, 575-8.
62. (1987) Symposium on Linkage of von Recklinghausen Neurofibromatosis (NF1). Closing in on the gene for von Recklinghausen neurofibromatosis, *Genomics*, 1, 335-83.
63. SARFARAZI, M., HUSON, S. M. & EDWARDS, J. H. (1987) An exclusion map for Von Recklinghausen neurofibromatosis, *J Med Genet*, 24, 515-20.
64. CAWTHON, R. M., ANDERSEN, L. B., BUCHBERG, A. M. et al. (1991) cDNA sequence and genomic structure of EV12B, a gene lying within an intron of the neurofibromatosis type 1 gene, *Genomics*, 9, 446-60.

65. VISKOCHIL, D., BUCHBERG, A. M., XU, G. et al. (1990) Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus, *Cell*, 62, 187-92.
66. WALLACE, M. R., MARCHUK, D. A., ANDERSEN, L. B. et al. (1990) Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients, *Science*, 249, 181-6.
67. MARCHUK, D. A., SAULINO, A. M., TAVAKKOL, R. et al. (1991) cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product, *Genomics*, 11, 931-40.
68. LI, Y., O'CONNELL, P., BREIDENBACH, H. H. et al. (1995) Genomic organization of the neurofibromatosis 1 gene (NF1), *Genomics*, 25, 9-18.
69. UPADHYAYA, M., SHEN, M., CHERRYSON, A. et al. (1992) Analysis of mutations at the neurofibromatosis 1 (NF1) locus, *Hum Mol Genet*, 1, 735-40.
70. CROWE, F. W., SCHULL, W. J. & NEEL, J. V. (1956). A clinical, pathological and genetic study of multiple neurofibromatosis. Springfield, Illinois, C. C. Thomas, pp. 142-6.
71. RICCARDI, V. M. (1992) Neurofibromatosis: phenotype, natural history, and pathogenesis. Baltimore, MD: John Hopkins University Press.
72. DASTON, M. M., SCRABLE, H., NORDLUND, M. et al. (1992) The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytes, *Neuron*, 8, 415-28.
73. HUYNH, D. P., LIN, C. T. & PULST, S. M. (1992) Expression of neurofibromin, the neurofibromatosis 1 gene product: studies in human neuroblastoma cells and rat brain, *Neurosci Lett*, 143, 233-6.
74. CANCE, W. G., BRENNAN, M. F., DUDAS, M. E., HUANG, C. M. & CORDON-CARDO, C. (1990) Altered expression of the retinoblastoma gene product in human sarcomas, *N Engl J Med*, 323, 1457-62.
75. XU, G. F., O'CONNELL, P., VISKOCHIL, D. et al. (1990) The neurofibromatosis type 1 gene encodes a protein related to GAP, *Cell*, 62, 599-608.
76. SEIZINGER, B. R. (1993) NF1: a prevalent cause of tumorigenesis in human cancers?, *Nat Genet*, 3, 97-9.
77. TANG, Y., MARWAHA, S., RUTKOWSKI, J. L. et al. (1998) A role for Pak protein kinases in Schwann cell transformation, *Proc Natl Acad Sci U S A*, 95, 5139-44.
78. INGRAM, D. A., HIATT, K., KING, A. J. et al. (2001) Hyperactivation of p21(ras) and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the prolifera-

- tion of neurofibromin-deficient mast cells in vivo and in vitro, *J Exp Med*, 194, 57-69.
79. YANG, F. C., INGRAM, D. A., CHEN, S. et al. (2003) Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1^{+/-} mast cells, *J Clin Invest*, 112, 1851-61.
80. DONOVAN, S., SEE, W., BONIFAS, J., STOKOE, D. & SHANNON, K. M. (2002) Hyperactivation of protein kinase B and ERK have discrete effects on survival, proliferation, and cytokine expression in Nf1-deficient myeloid cells, *Cancer Cell*, 2, 507-14.
81. ZHANG, Y. Y., VIK, T. A., RYDER, J. W. et al. (1998) Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines, *J Exp Med*, 187, 1893-902.
82. THE, I., HANNIGAN, G. E., COWLEY, G. S. et al. (1997) Rescue of a Drosophila NF1 mutant phenotype by protein kinase A, *Science*, 276, 791-4.
83. GUO, H. F., THE, I., HANNAN, F., BERNARDS, A. & ZHONG, Y. (1997) Requirement of Drosophila NF1 for activation of adenylyl cyclase by PACAP38-like neuropeptides, *Science*, 276, 795-8.
84. WASCHEK, J. A. (2002) Multiple actions of pituitary adenylyl cyclase activating peptide in nervous system development and regeneration, *Dev Neurosci*, 24, 14-23.
85. RODENHISER, D. I., COULTER-MACKIE, M. B. & SINGH, S. M. (1993) Evidence of DNA methylation in the neurofibromatosis type 1 (NF1) gene region of 17q11.2, *Hum Mol Genet*, 2, 439-44.
86. HAJRA, A., MARTIN-GALLARDO, A., TARLE, S. A. et al. (1994) DNA sequences in the promoter region of the NF1 gene are highly conserved between human and mouse, *Genomics*, 21, 649-52.
87. VISKOCHIL, D. (1998) Gene structure and expression, Chapter 3, In: Upadhyaya, M. & Cooper, D. (eds.) Neurofibromatosis type 1: from genotype to phenotype. Oxford, BIOS Scientific, pp 39-56.
88. KNUDSON, A. G. (2001) Two genetic hits (more or less) to cancer, *Nat Rev Cancer*, 1, 157-62.
89. DASGUPTA, B. & GUTMANN, D. H. (2003) Neurofibromatosis 1: closing the GAP between mice and men, *Curr Opin Genet Dev*, 13, 20-7.

90. BRANNAN, C. I., PERKINS, A. S., VOGEL, K. S. et al. (1994) Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues, *Genes Dev*, 8, 1019-29.
91. JACKS, T., SHIH, T. S., SCHMITT, E. M. et al. (1994) Tumour predisposition in mice heterozygous for a targeted mutation in Nf1, *Nat Genet*, 7, 353-61.
92. CICHOWSKI, K., SHIH, T. S., SCHMITT, E. et al. (1999) Mouse models of tumor development in neurofibromatosis type 1, *Science*, 286, 2172-6.
93. SKUSE, G. R., KOSCIOLEK, B. A. & ROWLEY, P. T. (1991) The neurofibroma in von Recklinghausen neurofibromatosis has a unicellular origin, *Am J Hum Genet*, 49, 600-7.
94. KLUWE, L., FRIEDRICH, R. E. & MAUTNER, V. F. (1999) Allelic loss of the NF1 gene in NF1-associated plexiform neurofibromas, *Cancer Genet Cytogenet*, 113, 65-9.
95. RUTKOWSKI, J. L., WU, K., GUTMANN, D. H., BOYER, P. J. & LEGIUS, E. (2000) Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1, *Hum Mol Genet*, 9, 1059-66.
96. SERRA, E., ROSENBAUM, T., WINNER, U. et al. (2000) Schwann cells harbor the somatic NF1 mutation in neurofibromas: evidence of two different Schwann cell subpopulations, *Hum Mol Genet*, 9, 3055-64.
97. SHERMAN, L. S., ATIT, R., ROSENBAUM, T., COX, A. D. & RATNER, N. (2000) Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts, *J Biol Chem*, 275, 30740-5.
98. ZHU, Y., GHOSH, P., CHARNAY, P., BURNS, D. K. & PARADA, L. F. (2002) Neurofibromas in NF1: Schwann cell origin and role of tumor environment, *Science*, 296, 920-2.
99. INGRAM, D. A., YANG, F. C., TRAVERS, J. B. et al. (2000) Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo, *J Exp Med*, 191, 181-8.
100. NIELSEN, G. P., STEMMER-RACHAMIMOV, A. O., INO, Y. et al. (1999) Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation, *Am J Pathol*, 155, 1879-84.
101. KOUREA, H. P., CORDON-CARDO, C., DUDAS, M., LEUNG, D. & WOODRUFF, J. M. (1999) Expression of p27(kip) and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas: the emerging role of p27(kip) in malignant transformation of neurofibromas, *Am J Pathol*, 155, 1885-91.

102. MENON, A. G., ANDERSON, K. M., RICCARDI, V. M. et al. (1990) Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis, *Proc Natl Acad Sci U S A*, 87, 5435-9.
103. BIRINDELLI, S., PERRONE, F., OGGIONNI, M. et al. (2001) Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors, *Lab Invest*, 81, 833-44.
104. LIAPIS, H., MARLEY, E. F., LIN, Y. & DEHNER, L. P. (1999) p53 and Ki-67 proliferating cell nuclear antigen in benign and malignant peripheral nerve sheath tumors in children, *Pediatr Dev Pathol*, 2, 377-84.
105. KINDBLUM, L. G., AHLDEN, M., MEIS-KINDBLUM, J. M. & STENMAN, G. (1995) Immunohistochemical and molecular analysis of p53, MDM2, proliferating cell nuclear antigen and Ki67 in benign and malignant peripheral nerve sheath tumours, *Virchows Arch*, 427, 19-26.
106. HALLING, K. C., SCHEITHAUER, B. W., HALLING, A. C. et al. (1996) p53 expression in neurofibroma and malignant peripheral nerve sheath tumor. An immunohistochemical study of sporadic and NF1-associated tumors, *Am J Clin Pathol*, 106, 282-8.
107. VOGEL, K. S., KLESSE, L. J., VELASCO-MIGUEL, S. et al. (1999) Mouse tumor model for neurofibromatosis type 1, *Science*, 286, 2176-9.
108. RICCARDI, V. M. (1987) Mast-cell stabilization to decrease neurofibroma growth. Preliminary experience with ketotifen, *Arch Dermatol*, 123, 1011-6.
109. RICCARDI, V. M. (1993) A controlled multiphase trial of ketotifen to minimize neurofibroma-associated pain and itching, *Arch Dermatol*, 129, 577-81.
110. GUPTA, A., COHEN, B. H., RUGGIERI, P., PACKER, R. J. & PHILLIPS, P. C. (2003) Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1, *Neurology*, 60, 130-2.
111. YAN, N., RICCA, C., FLETCHER, J. et al. (1995) Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype, *Cancer Res*, 55, 3569-75.
112. GURUJEYALAKSHMI, G., HOLLINGER, M. A. & GIRI, S. N. (1999) Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level, *Am J Physiol*, 276, L311-8.

113. IYER, S. N., GURUJEYALAKSHMI, G. & GIRI, S. N. (1999) Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis, *J Pharmacol Exp Ther*, 289, 211-8.
114. FERNER, R. E. & GUTMANN, D. H. (2002) International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis, *Cancer Res*, 62, 1573-7.
115. SANTORO, A., TURSZ, T., MOURIDSEN, H. et al. (1995) Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, *J Clin Oncol*, 13, 1537-45.
116. (1997) Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration, *Lancet*, 350, 1647-54.
117. SANGER, F., NICKLEN, S. & COULSON, A. R. (1977) DNA sequencing with chain-terminating inhibitors, *Proc Natl Acad Sci U S A*, 74, 5463-7.
118. PROBER, J. M., TRAINOR, G. L., DAM, R. J. et al. (1987) A system for rapid DNA sequencing with fluorescent chain-terminating dideoxynucleotides, *Science*, 238, 336-41.
119. ZOU, M. X., BUTCHER, D. T., SADIKOVIC, B. et al. (2004) Characterization of functional elements in the neurofibromatosis (NF1) proximal promoter region, *Oncogene*, 23, 330-9.
120. MANCINI, D. N., SINGH, S. M., ARCHER, T. K. & RODENHISER, D. I. (1999) Site-specific DNA methylation in the neurofibromatosis (NF1) promoter interferes with binding of CREB and SP1 transcription factors, *Oncogene*, 18, 4108-19.
121. JONES, P. A. & LAIRD, P. W. (1999) Cancer epigenetics comes of age, *Nat Genet*, 21, 163-7.
122. SAKAI, T., TOGUCHIDA, J., OHTANI, N. et al. (1991) Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene, *Am J Hum Genet*, 48, 880-8.
123. GREGER, V., DEBUS, N., LOHMANN, D. et al. (1994) Frequency and parental origin of hypermethylated RB1 alleles in retinoblastoma, *Hum Genet*, 94, 491-6.
124. GONZALEZ-ZULUETA, M., BENDER, C. M., YANG, A. S. et al. (1995) Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and

- transformed human tissues correlates with gene silencing, *Cancer Res*, 55, 4531-5.
125. STRAZZULLO, M., COSSU, A., BALDINU, P. et al. (2003) High-resolution methylation analysis of the hMLH1 promoter in sporadic endometrial and colorectal carcinomas, *Cancer*, 98, 1540-6.
126. FEINBERG, A. P. & TYCKO, B. (2004) The history of cancer epigenetics, *Nat Rev Cancer*, 4, 143-53.
127. HORAN, M. P., COOPER, D. N. & UPADHYAYA, M. (2000) Hypermethylation of the neurofibromatosis type 1 (NF1) gene promoter is not a common event in the inactivation of the NF1 gene in NF1-specific tumours, *Hum Genet*, 107, 33-9.
128. LUIJTEN, M., REDEKER, S., VAN NOESEL, M. M. et al. (2000) Microsatellite instability and promoter methylation as possible causes of NF1 gene inactivation in neurofibromas, *Eur J Hum Genet*, 8, 939-45.
129. FISHBEIN, L., EADY, B., SANEK, N., MUIR, D. & WALLACE, M. R. (2005) Analysis of somatic NF1 promoter methylation in plexiform neurofibromas and Schwann cells, *Cancer Genet Cytogenet*, 157, 181-6.
130. EBINGER, M., SENF, L., WACHOWSKI, O. & SCHEURLEN, W. (2005) No aberrant methylation of neurofibromatosis 1 gene (NF1) promoter in pilocytic astrocytoma in childhood, *Pediatr Hematol Oncol*, 22, 83-7.
131. WONG, D. J., PAULSON, T. G., PREVO, L. J. et al. (2001) p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium, *Cancer Res*, 61, 8284-9.
132. BIAN, Y. S., OSTERHELD, M. C., FONTOLLIET, C., BOSMAN, F. T. & BENHATTAR, J. (2002) p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus, *Gastroenterology*, 122, 1113-21.
133. NUOVO, G. J., PLAIA, T. W., BELINSKY, S. A., BAYLIN, S. B. & HERMAN, J. G. (1999) In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis, *Proc Natl Acad Sci U S A*, 96, 12754-9.
134. KANG, G. H., SHIM, Y. H., JUNG, H. Y. et al. (2001) CpG island methylation in premalignant stages of gastric carcinoma, *Cancer Res*, 61, 2847-51.
135. WAKI, T., TAMURA, G., TSUCHIYA, T. et al. (2002) Promoter methylation status of E-cadherin, hMLH1, and p16 genes in nonneoplastic gastric epithelia, *Am J Pathol*, 161, 399-403.

136. CHAN, A. O., BROADDUS, R. R., HOULIHAN, P. S. et al. (2002) CpG island methylation in aberrant crypt foci of the colorectum, *Am J Pathol*, 160, 1823-30.
137. SUZUKI, H., WATKINS, D. N., JAIR, K. W. et al. (2004) Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer, *Nat Genet*, 36, 417-22.
138. TOYOTA, M., AHUJA, N., OHE-TOYOTA, M. et al. (1999) CpG island methylator phenotype in colorectal cancer, *Proc Natl Acad Sci U S A*, 96, 8681-6.
139. CHAN, A. O., ISSA, J. P., MORRIS, J. S., HAMILTON, S. R. & RASHID, A. (2002) Concordant CpG island methylation in hyperplastic polyposis, *Am J Pathol*, 160, 529-36.
140. HARDER, A., ROSCHE, M., REUSS, D. E. et al. (2004) Methylation analysis of the neurofibromatosis type 1 (NF1) promoter in peripheral nerve sheath tumours, *Eur J Cancer*, 40, 2820-8.
141. FEINBERG, A. P. & VOGELSTEIN, B. (1983) Hypomethylation distinguishes genes of some human cancers from their normal counterparts, *Nature*, 301, 89-92.
142. FEINBERG, A. P. & VOGELSTEIN, B. (1983) Hypomethylation of ras oncogenes in primary human cancers, *Biochem Biophys Res Commun*, 111, 47-54.
143. GHAZI, H., GONZALES, F. A. & JONES, P. A. (1992) Methylation of CpG-island-containing genes in human sperm, fetal and adult tissues, *Gene*, 114, 203-10.
144. DE SMET, C., DE BACKER, O., FARAONI, I. et al. (1996) The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation, *Proc Natl Acad Sci U S A*, 93, 7149-53.
145. HANSEN, R. S., WIJMEGA, C., LUO, P. et al. (1999) The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome, *Proc Natl Acad Sci U S A*, 96, 14412-7.
146. XU, G. L., BESTOR, T. H., BOURC'HIS, D. et al. (1999) Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene, *Nature*, 402, 187-91.
147. EDEN, A., GAUDET, F., WAGHMARE, A. & JAENISCH, R. (2003) Chromosomal instability and tumors promoted by DNA hypomethylation, *Science*, 300, 455.
148. COLMAN, S. D., WILLIAMS, C. A. & WALLACE, M. R. (1995) Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene, *Nat Genet*, 11, 90-2.

149. DASCHNER, K., ASSUM, G., EISENBARTH, I. et al. (1997) Clonal origin of tumor cells in a plexiform neurofibroma with LOH in NF1 intron 38 and in dermal neurofibromas without LOH of the NF1 gene, *Biochem Biophys Res Commun*, 234, 346-50.
150. JOHN, A. M., RUGGIERI, M., FERNER, R. & UPADHYAYA, M. (2000) A search for evidence of somatic mutations in the NF1 gene, *J Med Genet*, 37, 44-9.
151. SERRA, E., PUIG, S., OTERO, D. et al. (1997) Confirmation of a double-hit model for the NF1 gene in benign neurofibromas, *Am J Hum Genet*, 61, 512-9.
152. BHATTACHARYA, S. K., RAMCHANDANI, S., CERVONI, N. & SZYF, M. (1999) A mammalian protein with specific demethylase activity for mCpG DNA, *Nature*, 397, 579-83.
153. BESTOR, T., LAUDANO, A., MATTALIANO, R. & INGRAM, V. (1988) Cloning and sequencing of a cDNA encoding DNA methyltransferase of mouse cells. The carboxyl-terminal domain of the mammalian enzymes is related to bacterial restriction methyltransferases, *J Mol Biol*, 203, 971-83.
154. BRUNIQUEL, D. & SCHWARTZ, R. H. (2003) Selective, stable demethylation of the interleukin-2 gene enhances transcription by an active process, *Nat Immunol*, 4, 235-40.
155. SANTOS, F., HENDRICH, B., REIK, W. & DEAN, W. (2002) Dynamic reprogramming of DNA methylation in the early mouse embryo, *Dev Biol*, 241, 172-82.
156. HSIEH, C. L. (1999) Evidence that protein binding specifies sites of DNA demethylation, *Mol Cell Biol*, 19, 46-56.
157. DE SMET, C., LORIOT, A. & BOON, T. (2004) Promoter-dependent mechanism leading to selective hypomethylation within the 5' region of gene MAGE-A1 in tumor cells, *Mol Cell Biol*, 24, 4781-90.
158. NARAYAN, A., JI, W., ZHANG, X. Y. et al. (1998) Hypomethylation of pericentromeric DNA in breast adenocarcinomas, *Int J Cancer*, 77, 833-8.
159. RIBIERAS, S., SONG-WANG, X. G., MARTIN, V. et al. (1994) Human breast and colon cancers exhibit alterations of DNA methylation patterns at several DNA segments on chromosomes 11p and 17p, *J Cell Biochem*, 56, 86-96.
160. USHIJIMA, T., MORIMURA, K., HOSOYA, Y. et al. (1997) Establishment of methylation-sensitive-representational difference analysis and isolation of hypo- and hypermethylated genomic fragments in mouse liver tumors, *Proc Natl Acad Sci U S A*, 94, 2284-9.

161. EHRLICH, M., JIANG, G., FIALA, E. et al. (2002) Hypomethylation and hypermethylation of DNA in Wilms tumors, *Oncogene*, 21, 6694-702.
162. PINI, J. T., FRANCHINA, M., TAYLOR, J. M. & KAY, P. H. (2004) Evidence that general genomic hypomethylation and focal hypermethylation are two independent molecular events of non-Hodgkin's lymphoma, *Oncol Res*, 14, 399-405.
163. GONZALEZ-GOMEZ, P., BELLO, M. J., ARJONA, D. et al. (2003) Aberrant CpG island methylation in neurofibromas and neurofibrosarcomas, *Oncol Rep*, 10, 1519-23.
164. GONZALGO, M. L., HAYASHIDA, T., BENDER, C. M. et al. (1998) The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines, *Cancer Res*, 58, 1245-52.
165. ABE, M., OKOCHI, E., KURAMOTO, T. et al. (2002) Cloning of the 5' upstream region of the rat p16 gene and its role in silencing, *Jpn J Cancer Res*, 93, 1100-6.
166. DENG, G., CHEN, A., HONG, J., CHAE, H. S. & KIM, Y. S. (1999) Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression, *Cancer Res*, 59, 2029-33.
167. MIYAKURA, Y., SUGANO, K., KONISHI, F. et al. (2001) Extensive methylation of hMLH1 promoter region predominates in proximal colon cancer with microsatellite instability, *Gastroenterology*, 121, 1300-9.
168. YAN, P. S., SHI, H., RAHMATPANAH, F. et al. (2003) Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer, *Cancer Res*, 63, 6178-86.
169. MONTMINY, M. R., GONZALEZ, G. A. & YAMAMOTO, K. K. (1990) Regulation of cAMP-inducible genes by CREB, *Trends Neurosci*, 13, 184-8.
170. YAMAMOTO, K. K., GONZALEZ, G. A., BIGGS, W. H., 3RD & MONTMINY, M. R. (1988) Phosphorylation-induced binding and transcriptional efficacy of nuclear factor CREB, *Nature*, 334, 494-8.
171. GUTMANN, D. H., TENNEKON, G. I., COLE, J. L., COLLINS, F. S. & RUTKOWSKI, J. L. (1993) Modulation of the neurofibromatosis type 1 gene product, neurofibromin, during Schwann cell differentiation, *J Neurosci Res*, 36, 216-23.
172. UPADHYAYA & COOPER. (1977) Construction of expression plasmids from 5' flanking sequence adjacent to the NF1 gene, In: Viskochil, D. (eds.) Neurofibromatosis type 1, London, Bios Sci Publ, p. 49.

173. GETMAN, D. K., MUTERO, A., INOUE, K. & TAYLOR, P. (1995) Transcription factor repression and activation of the human acetylcholinesterase gene, *J Biol Chem*, 270, 23511-9.
174. JIANG, J. G., DEFRANCES, M. C., MACHEN, J., JOHNSON, C. & ZARNEGAR, R. (2000) The repressive function of AP2 transcription factor on the hepatocyte growth factor gene promoter, *Biochem Biophys Res Commun*, 272, 882-6.
175. COMB, M. & GOODMAN, H. M. (1990) CpG methylation inhibits proenkephalin gene expression and binding of the transcription factor AP-2, *Nucleic Acids Res*, 18, 3975-82.
176. STEWART, H. J., BRENNAN, A., RAHMAN, M. et al. (2001) Developmental regulation and overexpression of the transcription factor AP-2, a potential regulator of the timing of Schwann cell generation, *Eur J Neurosci*, 14, 363-72.
177. BIRD, A. (2002) DNA methylation patterns and epigenetic memory, *Genes Dev*, 16, 6-21.
178. BESTOR, T. H. (2003) Unanswered questions about the role of promoter methylation in carcinogenesis, *Ann N Y Acad Sci*, 983, 22-7.
179. VEIGL, M. L., KASTURI, L., OLECHNOWICZ, J. et al. (1998) Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers, *Proc Natl Acad Sci U S A*, 95, 8698-702.
180. BAYLIN, S. & BESTOR, T. H. (2002) Altered methylation patterns in cancer cell genomes: cause or consequence?, *Cancer Cell*, 1, 299-305.
181. WOODRUFF, J. M., LOUREA, H. P., LOUIS, D. N. et al. (2000) Neurofibroma, In: Kleihues, P. et Cavenee, W. K. (eds.) World Health Organization classification of tumours, pathology and genetics of tumours of the nervous system. Lyon, IARC Press, pp. 167-8.
182. CARROLL, S. L. & STONECYPHER, M. S. (2004) Tumor suppressor mutations and growth factor signaling in the pathogenesis of NF1-associated peripheral nerve sheath tumors. I. The role of tumor suppressor mutations, *J Neuropathol Exp Neurol*, 63, 1115-23.
183. ESHLEMAN, J. R. & MARKOWITZ, S. D. (1996) Mismatch repair defects in human carcinogenesis, *Hum Mol Genet*, 5 Spec No, 1489-94.
184. SINSHEIMER, R. L. (1955) The action of pancreatic deoxyribonuclease. II. Isomeric dinucleotides, *J Biol Chem*, 215, 579-83.

185. GRUENBAUM, Y., STEIN, R., CEDAR, H. & RAZIN, A. (1981) Methylation of CpG sequences in eukaryotic DNA, *FEBS Lett*, 124, 67-71.
186. TOTH, M., MULLER, U. & DOERFLER, W. (1990) Establishment of de novo DNA methylation patterns. Transcription factor binding and deoxycytidine methylation at CpG and non-CpG sequences in an integrated adenovirus promoter, *J Mol Biol*, 214, 673-83.
187. WOODCOCK, D. M., LAWLER, C. B., LINSENMEYER, M. E., DOHERTY, J. P. & WARREN, W. D. (1997) Asymmetric methylation in the hypermethylated CpG promoter region of the human L1 retrotransposon, *J Biol Chem*, 272, 7810-6.
188. CLARK, S. J., HARRISON, J. & FROMMER, M. (1995) CpNpG methylation in mammalian cells, *Nat Genet*, 10, 20-7.
189. FRANCHINA, M. & KAY, P. H. (2000) Evidence that cytosine residues within 5'-CCTGG-3' pentanucleotides can be methylated in human DNA independently of the methylating system that modifies 5'-CG-3' dinucleotides, *DNA Cell Biol*, 19, 521-6.
190. WHITE, G. P., WATT, P. M., HOLT, B. J. & HOLT, P. G. (2002) Differential patterns of methylation of the IFN-gamma promoter at CpG and non-CpG sites underlie differences in IFN-gamma gene expression between human neonatal and adult CD45RO- T cells, *J Immunol*, 168, 2820-7.
191. HAINES, T. R., RODENHISER, D. I. & AINSWORTH, P. J. (2001) Allele-specific non-CpG methylation of the Nf1 gene during early mouse development, *Dev Biol*, 240, 585-98.
192. MALONE, C. S., MINER, M. D., DOERR, J. R. et al. (2001) CmC(A/T)GG DNA methylation in mature B cell lymphoma gene silencing, *Proc Natl Acad Sci U S A*, 98, 10404-9.
193. KOUIDOU, S., AGIDOU, T., KYRKOU, A. et al. (2005) Non-CpG cytosine methylation of p53 exon 5 in non-small cell lung carcinoma, *Lung Cancer*, 50, 299-307.
194. OLEK, A., OSWALD, J. & WALTER, J. (1996) A modified and improved method for bisulphite based cytosine methylation analysis, *Nucleic Acids Res*, 24, 5064-6.
195. AOKI, A., SUETAKE, I., MIYAGAWA, J. et al. (2001) Enzymatic properties of de novo-type mouse DNA (cytosine-5) methyltransferases, *Nucleic Acids Res*, 29, 3506-12.

196. INOUE, S. & OISHI, M. (2005) Effects of methylation of non-CpG sequence in the promoter region on the expression of human synaptotagmin XI (syt11), *Gene*, 348, 123-34.
197. CHAO, W., HUYNH, K. D., SPENCER, R. J., DAVIDOW, L. S. & LEE, J. T. (2002) CTCF, a candidate trans-acting factor for X-inactivation choice, *Science*, 295, 345-7.